---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-021214"
form_type: "8-K"
ticker: "PSNL"
cik: "0001527753"
company_name: "Personalis, Inc."
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T13:40:57.471805+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Personalis Q3 revenue $14.9M; core biopharma up 73% YoY; FY2022 guidance issued

## Summary
- Q3 2022 revenue $14.9M vs $22.3M in Q3 2021; biopharma ex-VA revenue $14.9M (+73% YoY).
- Net loss $26.5M ($0.58 EPS) vs net loss in prior year; cash $192.8M as of Sept 30, 2022.
- FY2022 guidance: total revenue $63-64M, biopharma ex-VA $55.5-56.5M, net loss $111-114M.
- Won exclusive 5-year VA MVP contract (subject to bidder protest); initial order received.
- Appointed Christopher Hall as SVP, Diagnostic Business; launched NeXT Dx marketing and research collaborations with BC Cancer and Duke.

## SEC filing metadata
- accession: 0000950170-22-021214
- form_type: 8-K
- ticker: PSNL
- cik: 0001527753
- company_name: Personalis, Inc.
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527753/000095017022021214/0000950170-22-021214-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527753/000095017022021214/psnl-20221102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-021214
- JSON: https://secwatch.observer/filing/0000950170-22-021214.json
- Plain text: https://secwatch.observer/filing/0000950170-22-021214.txt

## Key facts
- Earnings Releases
  Personalis, Inc. reported the full year of 2022 results: revenue in the range of $63.0 million to $64.0 million, net income in the range of $111.0 million to $114.0 million. Guidance initiated.
  - Period: the full year of 2022
  - Revenue: in the range of $63.0 million to $64.0 million
  - Net income: in the range of $111.0 million to $114.0 million
  - Guidance: initiated
  - Result: guidance update
  source text: Full Year 2022 Outlook Personalis expects the following for the full year of 2022: • Total company revenue is expected to be in the range of $63.0 million to $64.0 million • Revenue from biopharma and all other customers, excluding the VA MVP, is expected to be in the range of $55.5 million to $56.5 million • Net loss is expected to be in the range of $111.0 million to $114.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1527753/000095017022021214/0000950170-22-021214-index.htm
- Earnings Releases
  Personalis, Inc. reported the third quarter ended September 30, 2022 results: revenue $14.9 million, net income $26.5 million, EPS $0.58.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $14.9 million
  - Net income: $26.5 million
  - EPS: $0.58
  - Result: reported results
  source text: Revenue was $14.9 million in the three months ended September 30, 2022 • Gross margin was 16.7% in the three months ended September 30, 2022 • Operating expenses were $29.7 million in the three months ended September 30, 2022 • Net loss was $26.5 million in the three months ended September 30, 2022, and net loss per share was $0.58 based on a weighted-average basic and diluted share count of 45.9 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1527753/000095017022021214/0000950170-22-021214-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.